ArticleCell death and differentiation2026
LINC 02086, a novel biomarker for early detection of gastric cancer and a target for cancer therapy.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- H2AC19 promotes lung adenocarcinoma progressionActa pharmaceutica Sinica. B · 2026Article
- Circular RNA circAHSA1 serves as a stable serum biomarker for the diagnosis and progression of gastric cancer.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a significant global health challenge, often diagnosed at advanced stages due to the absence of reliable early detection biomarkers. In this study, we collected serum samples from multicenter, demonstrating elevated serum levels of LINC 02086 exhibit high diagnostic accuracy. LINC 02086 significantly upregulated in GC tissues, with its expression correlating with poor patient survival. As a driving factor of GC, Helicobacter pylori infection upregulates LINC 02086. Mechanistically, we found METTL3-mediated N6-methyladenosine modification of LINC 02086 promotes GC progression, which upregulates HuR by sponging miRNA-139. We also explored the therapeutic potential of LINC 02086-targeted siRNA delivered via lipid nanoparticles, showing significant inhibition of GC growth and metastasis. These findings position LINC 02086 as a promising serum biomarker for early GC detection and as a potential therapeutic target, paving the way for improved diagnostic and treatment strategies in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.